论文部分内容阅读
本文对中枢作用的α_2受体激动剂莫索尼定(Moxonidin)、盐酸可乐定治疗高血压的疗效和耐受性作双盲随机对照试验。152例轻、中度高血压患者,在研究前2周停用药物。患者在开始的2～3周内每天早晨接受安慰剂,使收缩压>160mmHg,舒张压>95mmHg。然后给予口服莫索尼定(122例)或可乐定(30例)6周。初始剂量为每天早晨0.2mg,6小时后测量血压,如血压下降不达到10%或5%,则于治疗第3天起剂量增至每日0.4 mg,当第5天舒张压仍高于90mm-Hg以上,则每晚增服1次0.2 mg。6周后,患者再接受安慰剂3天。
In this paper, a double-blind, randomized, controlled trial of the efficacy and tolerability of centrally acting α 2 -receptor agonist Moxonidin and clonidine hydrochloride in the treatment of hypertension was conducted. 152 patients with mild to moderate hypertension were discontinued 2 weeks prior to study. Patients received placebo every morning for a period of 2 to 3 weeks beginning with systolic blood pressure> 160 mmHg and diastolic blood pressure> 95 mmHg. Moxodine was given orally (n = 122) or clonidine (n = 30) for 6 weeks. The initial dose of 0.2mg every morning, 6 hours after the measurement of blood pressure, such as blood pressure drops do not reach 10% or 5%, the dose on the 3rd day of treatment increased to 0.4 mg daily, when the 5th day diastolic blood pressure is still higher than 90mm -Hg above, then add 1 night 0.2 mg. After 6 weeks, the patients received another placebo for 3 days.